Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Value Peer-spectives
Filter by Topic
ASCO’s Value Framework
Commentary
Employers’ Perspective
Letter to our Readers
Oncologist–Patient Communication
Patient Communication
Patient Perspective
Payer’s Perspective
Practice Management
Testimonials
The Patient Perspective
Value in Oncology
Value Propositions
VBCC Perspectives
New Biomarker a Promising Development in Ewing’s Sarcoma
Value Propositions
,
Value Peer-spectives
July 2012, Vol 3, No 5
A team of researchers from the University of Colorado led by Tyler Robin, PhD, Department of OB/GYN, Denver Anschutz Medical Campus, has discovered a new biomarker in Ewing’s sarcoma that explains the lack of disease response to current chemotherapy in some patients with this cancer, who until now have had a very poor prognosis.
Read Article
Precision Diagnostics Currently the True Value of Personalized Medicine
Value Propositions
,
Value Peer-spectives
July 2012, Vol 3, No 5
>According to Genome Health Solutions cofounder Mark S. Boguski, MD, PhD, FCAP, Harvard Medical School’s Center for Biomedical Informatics and Beth Israel Deaconess Medical Center, at this point in time, the promise of genomics lies “not so much in therapeutics or disease prevention, but in precision diagnostics that will really enable personalized medicine.
Read Article
Integrating Digital Patient Engagement into Your Care Model
By
Gena Cook
Practice Management
,
Value Peer-spectives
June 2012, Vol 3, No 4
The Health Information Technology for Economic and Clinical Health (HITECH) Act has set aside $19 billion in incentives to encourage healthcare providers to adopt and meaningfully use electronic medical record (EMR) technology in an effort to provide more patient-centered care.
Read Article
Will Merger of 2 Major Diagnostic Centers Up Access to Molecular Imaging?
Value Propositions
,
Value Peer-spectives
June 2012, Vol 3, No 4
Two of the largest diagnostic imaging centers in the country—Insight Imaging in California and Centers for Diagnostic Imaging (CDI) in Minneapolis—have announced that they are merging forces.
Read Article
Radium-223 Offers New Hope for Patients with Bone Metastases
Value Propositions
,
Value Peer-spectives
June 2012, Vol 3, No 4
At the 2012 annual meeting of the Society of Nuclear Medicine, researchers presented new results for the radioisotope therapy radium-223 chloride, suggesting that these results represent a new treatment protocol for patients with advanced prostate cancer that has spread to the bone.
Read Article
Understanding Genes Is Crucial to Predicting Response to Breast Cancer Therapy
Value Propositions
,
Value Peer-spectives
June 2012, Vol 3, No 4
A study funded by the National Cancer Institute, the National Institutes of Health, a Theodore N. Law Endowment for Scientific Achievement, and a Dodie P. Hawn Fellowship in Cancer Genetics Research surprisingly showed that the presence of normal
p53
, a tumor suppressor gene and not the mutated gene, was making chemotherapy with doxorubicin less effective in breast cancer; it is the mutated gene that actually enhances the benefit of the drug and not the reverse.
Read Article
In a Policy Reversal, FDA Concedes Value of Accelerating Approval of Early-Stage Breast Cancer Drugs
Value Propositions
,
Value Peer-spectives
June 2012, Vol 3, No 4
The FDA has reversed its long-standing policy regarding breast cancer trials that could greatly reduce the time and cost of new drug development for early-stage breast cancer.
Read Article
Personalized Medicine the “Crown Jewel” of Drug Development
Value Propositions
,
Value Peer-spectives
June 2012, Vol 3, No 4
The recent trend in drug development of shifting away from one-size-fits-all cancer medications to targeted therapies, which is the key to personalized medicine, points to the value of and monetary benefits of developing drugs that target the molecular levels of cancer cells.
Read Article
Mevion S250 Proton Therapy System Lowers Costs, Approved in Europe
Value Propositions
,
Value Peer-spectives
May 2012, Vol 3, No 3
The Mevion S250 Proton Therapy System has received marketing approval in Europe but is still pending clearance by the US Food and Drug Administration.
Read Article
Vaccine Showing Antitumor Activity: A New Paradigm in Cancer Therapy?
Value Propositions
,
Value Peer-spectives
May 2012, Vol 3, No 3
Injecting antibodies and T cells with cancer stem cells may signal a new paradigm for anticancer immunotherapy, according to a recent study.
Read Article
Page 11 of 16
6
7
8
9
10
11
12
13
14
15
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma